RxDoctor Payments Data

Janie Kwak Tran, MD

Internal Medicine · Las Vegas, NVNPI 1497847438

Payments from drug & device makers

$9,341in general payments, 2019–2025

Across 436 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • GSK$1K
  • Amarin Pharma, Inc.$646
  • Amgen$595
  • Novo Nordisk$479
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$1,20013%
  • Food & beverage$7,81884%
  • Education$3243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,341 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$119,737
Medicare patients
172
Services billed
1,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$21,627
FarxigaDapagliflozin Propanediol20$20,051
ProliaDenosumab11$18,664
JanuviaSitagliptin Phosphate11$17,212
OzempicSemaglutide14$16,673
RybelsusSemaglutide11$15,046
TradjentaLinagliptin17$13,443
JardianceEmpagliflozin16$12,978
VascepaIcosapent Ethyl17$11,957
Xigduo XrDapaglifloz Propaned/Metformin18$11,605
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,429
Tresiba Flextouch U-100Insulin Degludec17$6,728
SymbicortBudesonide/Formoterol Fumarate19$4,245
SynthroidLevothyroxine Sodium28$2,984
Atorvastatin Calcium244$1,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$479$31,72025 claims
Boehringer IngelheimTradjenta, Jardiance$187$26,42033 claims
AstraZenecaFarxiga, Symbicort$1,995$24,29639 claims
PfizerEliquis$307$21,62735 claims
AmgenProlia$595$18,66411 claims
MerckJanuvia$120$17,21211 claims
GSKTrelegy Ellipta$1,068$7,42912 claims
AbbVieSynthroid$350$2,98428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →